The company launched in 2022 and has scaled quickly
Science 291, 17551759
This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input. If the FDA moves forward with its proposal, this would be a victory for drug manufacturers, and loss for drug compounders, in the drug compounding debate over GLP-1 drugs sold for weight loss and type 2 diabetes
Like other incretin-based medications, the most common side effects were gastrointestinal: Common Side Effects Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration) Diarrhea: Approximately 20-35% of participants Vomiting: Approximately 10-20% of participants Constipation: Approximately 10-15% of participants Decreased appetite: Common and expected given the mechanism of action Less Common but Notable Effects Increased heart rate: Small elevations in resting heart rate were observed, consistent with other GLP-1 class medications Injection site reactions: Mild redness or itching at injection sites Fatigue: Reported by some participants, particularly during dose escalation Most adverse events were mild to moderate and occurred primarily during the dose escalation phase
It works by enhancing insulin secretion and reducing appetite
However, rapid escalation should only be done under medical supervision to avoid side effects like nausea and dizziness
